Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 11/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25752898 | 0.84 | RAB9A (0.50) | RAB9AMAPTKDM4ENPC1KMT2A | |
| SCHEMBL851343 | 0.84 | DEGS1 (0.56) | GSK3BDYRK1A | |
| SCHEMBL6609814 | 0.84 | NAMPT (0.52) | RAB9ANPC1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL2056409 | 0.83 | RAB9A (0.70) | RAB9AMAPTKDM4ENPC1KMT2A | |
| SCHEMBL56219 | 0.83 | PTGS1 (0.50) | RAB9AMAPTGSK3BDYRK1A | |
| SCHEMBL30231113 | 0.83 | GSK3B (0.44) | RAB9AMAPTGSK3BDYRK1A | |
| SCHEMBL12461458 | 0.83 | GSK3B (0.44) | RAB9AMAPTGSK3BDYRK1A | |
| SCHEMBL283737 | 0.83 | RAB9A (0.51) | RAB9AMAPTKDM4ENPC1KMT2A | |
| SCHEMBL29372377 | 0.83 | RAB9A (0.51) | RAB9AMAPTKDM4ENPC1KMT2A | |
| SCHEMBL4398253 | 0.83 | GSK3B (0.44) | RAB9AMAPTGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | claimed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| US-11427542-B2 | Compounds for treatment of cardiac arrhythmias and heart failure | ELEX BIOTECH, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210139429-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | ELEX BIOTECH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| WO-2019191502-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | ELEX BIOTECH, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019149260-A1 | PYRIDAZINOL COMPOUND, DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2019-08-08 | — | — | WO | disclosed |
| CN-107935988-A | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2018-04-20 | — | — | CN | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
| CN-105636945-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2017-11-17 | — | — | CN | disclosed |
| WO-2009141386-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| CN-1950357-A | Imidazole derivatives used as TAFIA inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-04-18 | — | — | CN | disclosed |
| US-20050107468-A1 | Process for the preparation of an enantiomerically enriched thio compound | DSM IP ASSETS B.V. (NL) | 2005-05-19 | — | — | US | disclosed |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-1453797-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND | DSM IP Assets B.V. (NL) | 2004-09-08 | — | — | EP | disclosed |
| EP-1325908-A1 | Process for the preparation of an enantiomerically enriched thio compound | DSM N.V. (NL) | 2003-07-09 | — | — | EP | disclosed |
| WO-2003051827-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND | DSM IP ASSETS B.V. (NL) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139429-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | RYR2, RYR1, CACNA1F | RAB9A 1444/4885MAPT 341/4885KDM4E 3952/4885 |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | RAB9A 3078/4885MAPT 4864/4885KDM4E 1858/4885 |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | RAB9A 2350/4885MAPT 4858/4885KDM4E 3273/4885 |
| US-11427542-B2 | Compounds for treatment of cardiac arrhythmias and heart failure | RYR2, RYR1, CACNA1F | RAB9A 1444/4885MAPT 341/4885KDM4E 3952/4885 |
| US-20050107468-A1 | Process for the preparation of an enantiomerically enriched thio compound | SLC7A1, TCP1, TFRC | RAB9A 716/4885MAPT 4599/4885KDM4E 2320/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | RAB9A 1615/4885MAPT 103/4885KDM4E 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.